Lista de obras -

A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

artículo científico publicado en 2012

Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

artículo científico publicado en 2010

Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.

artículo científico publicado en 2007

Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users.

artículo científico publicado en 2016

Coupling effects on photoluminescence of exciton states in asymmetric quantum dot molecules

artículo científico publicado en 2014

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients

artículo científico publicado en 2012

Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.

artículo científico publicado en 2012

Excitonic effects on the second-order nonlinear optical properties of semi-spherical quantum dots ⬇️

artículo científico publicado el 29 de marzo de 2011

High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease

artículo científico publicado en 2014

IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.

artículo científico publicado en 2015

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse

artículo científico publicado en 2011

Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.

artículo científico publicado en 2013

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

artículo científico publicado en 2011

Influence of the Combination of Low-Density Lipoprotein Receptor and Interleukin 28B Genotypes on Lipid Plasma Levels in HIV/Hepatitis C-Coinfected Patients

article

Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry.

artículo científico publicado en 2010

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.

artículo científico publicado en 2012

Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis.

artículo científico publicado en 2009

Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.

artículo científico publicado en 2013

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

artículo científico publicado en 2011

Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.

artículo científico publicado en 2015

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

artículo científico publicado en 2011

Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.

artículo científico publicado en 2009

Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients

artículo científico publicado en 2013

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

artículo científico publicado en 2013

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

artículo científico publicado en 2010

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

artículo científico publicado en 2011

Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.

artículo científico publicado en 2010

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.

artículo científico publicado en 2015

Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

artículo científico publicado en 2013

Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

artículo científico publicado en 2013

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

artículo científico publicado en 2007

Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.

artículo científico publicado en 2011

Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients

artículo científico publicado en 2006

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.

artículo científico publicado en 2013

Lista de obras de

A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.

Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users.

Coupling effects on photoluminescence of exciton states in asymmetric quantum dot molecules

Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients

Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.

Excitonic effects on the second-order nonlinear optical properties of semi-spherical quantum dots ⬇️

High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease

IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse

Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV.

Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

Influence of the Combination of Low-Density Lipoprotein Receptor and Interleukin 28B Genotypes on Lipid Plasma Levels in HIV/Hepatitis C-Coinfected Patients

Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry.

LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.

Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis.

Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.

Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients

Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.

Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis.

Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.

Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.

The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.

Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.

Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients

Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.